Global clinical trials activity increased by 9% in Q1 2021, when compared with the same quarter in 2020, according to GlobalData.
Industry sponsored trials accounted for a 51.4% share of overall activity in Q1 2021, an increase of 11.2% when compared with Q1 2020.
Non-industry sponsored trials accounted for a 48.6% share of all clinical trials in Q1 2021, marking a decrease of 11.2% when compared with the same period in 2020.
Q1 2021 industry sponsored clinical trials activity by therapy areas
Oncology was the leading therapy area for industry sponsored clinical trials in Q1 2021, accounting for a 29.6% share of all trials.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
This was followed by Infectious Disease with an 18.4% share, Central Nervous System with 13.4%, Metabolic Disorders with 7.4% and Cardiovascular with 6.4%.
In Q1 2020, Oncology led with a 25.4% share, followed by Infectious Disease with 16.9%, Central Nervous System with 13.7%, Respiratory with 10.6%, and Cardiovascular with 8.4%.
|Industry sponsored trials: Q1 2021 vs Q1 2020|
|Therapy Area||Q1 2020||Q1 2021||Activity|
|Central Nervous System||13.7%||13.4%|
|Genito Urinary System And Sex Hormones||2.6%||2.2%|
|Ear Nose Throat Disorders||1.8%||1.0%|
|Mouth and Dental Disorders||0.8%||0.5%|
|Non Malignant Disorders||0.1%||0.0%|
Most active therapy areas in non-industry sponsored clinical trials
In Q1 2021 the leading therapy area for non-industry sponsored clinical trials was Oncology, accounting for a 27.9% share of all trials.
This was followed Central Nervous System with a 24.7% share, Infectious Disease with 16.7%, Cardiovascular with 9.2%, and Musculoskeletal Disorders with 5.0%.
In Q1 2020, Central Nervous System held the lead in non-industry sponsored clinical trials with a 21.9% share, followed by Infectious Disease with 20.2%, Oncology with 17.9%, Respiratory with 11.7%, and Cardiovascular with 8.8%.
|Non-Industry sponsored trials: Q1 2021 vs Q1 2020|
|Therapy Area||Q1 2020||Q1 2021||Activity|
|Central Nervous System||21.9%||24.7%|
|Genito Urinary System And Sex Hormones||2.7%||2.5%|
|Mouth and Dental Disorders||2.5%||1.7%|
|Ear Nose Throat Disorders||1.4%||0.9%|
|Non Malignant Disorders||0.3%||0.4%|
Asia-Pacific region has the most activity for industry sponsored clinical trials
Asia-Pacific was the most active region for industry sponsored clinical trials activity in Q1 2021 with a 46.8% share, compared with 52.1% in Q1 2020.
North America was the second most active region with a 38.2% share in Q1 2021, up from 32.6% in Q1 2020, followed by Europe with a 29.4% share in Q1 2021, down from 30.5% in Q1 2020.
Single country studies held an 83.5% share in industry sponsored clinical trials in Q1 2021, compared with 83.5% in Q1 2020. Multinational trials accounted for 16.5% in Q1 2021, against 16.5% in Q1 2020.
Regional activity for non-industry sponsored clinical trials
Asia-Pacific saw the most non-industry sponsored clinical trial activity in Q1 2021 with a 39.4% share, down from 51.7% in Q1 2020.
North America held the second position with a 27.6% share in Q1 2021, compared with 14.6% in Q1 2020. This was followed by Europe with a 20.3% share in Q1 2021, as against 15.5% in Q1 2020.
Single country studies accounted for 98.8% share of non-industry sponsored clinical trials in Q1 2021, compared with 99.1% in Q1 2020. Multinational trials accounted for a 1.2% share in Q1 2021, up from 0.9% in Q1 2020.
Clinical trials by phase in Q1 2021
Phase II trials outnumbered all other studies with a 39.5% share for industry sponsored trials in Q1 2021, compared with 35.8% in Q1 2020.
The share of Phase I trials stood at 31.0% in Q1 2021, down from 32.9% in Q1 2020. Phase III trials increased to 18.1% in Q1 2021, compared with 16.6% in Q1 2020, followed by Phase IV trials with an 11.4% share in Q1 2021, against 14.7% in Q1 2020.
For non-industry sponsored clinical trials, Phase II activity decreased to a 49.6% share in Q1 2021, compared with 41.5% in Q1 2020.
Phase IV trials were the second most active with a 21.5% share in Q1 2021, compared with 20.7% in Q1 2020. Phase I trials held a 14.5% share in Q1 2021, against 18.4% in Q1 2020, followed by Phase III trials with a 14.4% share in Q1 2021, over 19.5% in Q1 2020.
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.